Transfection-Induced Inflammatory Signaling in Hepatic Tissue

While the primary goal of transfection is gene delivery, the process inevitably interacts with the immune system. The liver, as a central immunological organ, contains various cell types (hepatocytes, Kupffer cells, liver sinusoidal endothelial cells, and infiltrating immune cells) that can mount inflammatory responses when they detect foreign genetic material. Transfection-induced inflammatory signaling refers to the cascade of immune activation events – from innate sensor engagement to cytokine release – triggered by the introduction of DNA or RNA into liver tissue. In the context of hepatic transfection, such inflammatory responses can manifest as elevated cytokine levels in blood, activation of nuclear factor kappa B (NF-κB) pathways in cells, and even systemic symptoms if severe.

This review examines the molecular mechanisms behind these immune responses. We highlight how different transfection methods (hydrodynamic injection, lipofection, polymer complexes) vary in their propensity to cause inflammation, and how careful design of vectors and reagents can mitigate these effects. Altogen Biosystems’ liver transfection tools are noted for their low immunogenic profiles, which is an important consideration for both research and therapeutic applications.

Innate Immune Sensing of Transfected DNA/RNA

The liver’s innate immune system is adept at sensing pathogen-associated molecular patterns (PAMPs), and foreign nucleic acids introduced via transfection can resemble viral or bacterial genetic material. Plasmid DNA containing unmethylated CpG dinucleotides, for instance, can be recognized by Toll-like receptor 9 (TLR9) in endosomes of immune cells (like Kupffer cells, the liver macrophages). Activation of TLR9 leads to downstream signaling that results in production of pro-inflammatory cytokines such as IL-6, IL-1β, TNF-α, and interferons. Notably, in many experiments, transfection of plasmid DNA has been observed to increase IL-6 levels, indicating activation of innate immune pathways. One study noted that delivering CpG-rich oligodeoxynucleotides complexed with a polycation caused IL-6 to rise from ~500 to ~1250 pg/mL in serum, alongside a surge in IFN-α, demonstrating a dose-dependent cytokine response to the DNA.

Cationic polymers like polyethyleneimine (PEI), common transfection reagents, can themselves stimulate immune cells. PEI/DNA complexes are taken up by liver cells and can cause endosomal disruption – a desired effect for gene delivery – but they may also alert the cell to danger. Research has shown that unmodified PEI can provoke significant secretion of IL-6, TNF-α and other inflammatory factors by cells. In one comparative study, hepatocyte-targeted HA-PEI (hyaluronic acid-conjugated PEI) was developed to reduce this issue: the modified polymer elicited much lower levels of IL-6, IL-1β, and TNF-α compared to standard PEI, which underscores how chemistry of the delivery vehicle influences immune activation. Similarly, certain lipid-based nanoparticles can trigger immune responses. Some cationic lipids may activate complement or interact with TLRs. However, lipid nanoparticles can be tuned – for example, by including polyethylene glycol (PEG) or altering lipid structures – to reduce recognition by the immune system.

Beyond TLR9, cytosolic DNA sensors such as cGAS (cyclic GMP-AMP synthase) are relevant. cGAS detects double-stranded DNA in the cytosol and produces a second messenger that activates STING, leading to type I interferon production. If plasmid DNA escapes into the cytosol of hepatocytes or immune cells, cGAS-STING can induce an antiviral-like state. The host cell also has mechanisms like TREX1 exonuclease that degrade cytosolic DNA to prevent over-activation of cGAS. Notably, studies have found that TREX1 swiftly degrades DNA that remains in the cytosol after transfection, thereby limiting interferon induction – when TREX1 is absent or inhibited, cytosolic DNA triggers a much stronger immune response. This means transfection can set off a tug-of-war: DNA triggers sensors, but the cell tries to eliminate the DNA. In any case, even transient presence of DNA can suffice to spur inflammatory signaling.

RNA-based transfection (e.g., siRNA, mRNA) engages different receptors. Double-stranded RNA or siRNA can be recognized by TLR3 (in endosomes) or RIG-I/MDA5 (in the cytosol), leading again to interferon and cytokine production. Chemical modification of synthetic RNA (such as 2’ O-methylation of uridine) is a known strategy to reduce these immunostimulatory effects. The liver’s response to RNA transfection is context-dependent: formulated siRNA (like lipid-complexed siRNA) tends to produce less overt inflammation than plasmid DNA because these siRNA molecules are often designed to avoid immune activation. Nonetheless, high doses or certain sequences can still trigger IL-6 and interferon release.

Inflammatory Outcomes and Mitigation in Liver Transfection

The consequences of inflammatory signaling after transfection range from mild and transient to significant. In hydrodynamic tail-vein injection of plasmids – a method where a large volume of DNA solution is rapidly injected – one might expect substantial immune activation due to the brute-force delivery. Interestingly, hydrodynamic delivery in mice is noted to induce only a weak immune response in itself when pure DNA in saline is used. It appears that naked DNA, without additional components, is relatively poor at activating immunity; many of the acute toxicities of hydrodynamic injection are mechanical (hydrostatic pressure causing tissue stress) rather than inflammatory. This contrasts with viral vector delivery, which often triggers stronger innate responses. In fact, a recent review pointed out that injection of plain plasmid in saline “only weakly activates host immunity,” whereas other gene delivery methods (including certain viral vectors or complex formulations) can cause more problematic activation. This is a reassuring insight for researchers using hydrodynamic gene transfer: the method is somewhat immuno-evasive on its own, though the physical stress and any expressed transgene (if it’s foreign) can still elicit immune responses subsequently.

For lipid and polymer-based systems, many improvements have been made to reduce inflammation. One example is the development of “lipidoid” nanoparticles for siRNA or DNA delivery to liver. These are lipid-like molecules that can complex nucleic acids. Investigators have created libraries of lipidoids and found formulations that achieve gene knockdown in hepatocytes with minimal cytokine release. In one study, a single intravenous dose of an optimized lipid nanoparticle carrying siRNA against an endogenous liver gene resulted in robust gene silencing with only mild cytokine elevations, and the gene silencing (e.g. of Pcsk9) persisted for weeks. Another clinically relevant approach is conjugating a targeting ligand to siRNA (e.g., N-acetylgalactosamine, GalNAc, which binds hepatocyte receptors). GalNAc-siRNA conjugates (such as the FDA-approved drug inclisiran) can be injected subcutaneously to silence liver genes with infrequent dosing and minimal systemic inflammation. These are specifically designed to avoid activating TLRs or other sensors – they deliver the siRNA specifically to hepatocytes via receptor-mediated uptake and incorporate chemical modifications that blunt innate recognition.

Altogen’s liver transfection reagents are explicitly formulated to minimize inflammatory and toxic side effects. The Altogen Liver In Vivo Transfection Reagent is described as having minimal toxicity in animal models. It forms stable complexes that presumably shield the nucleic acid from inappropriate recognition during circulation. By efficiently targeting liver cells and avoiding other tissues, it reduces the chance of immune cell activation elsewhere. Additionally, since it is biodegradable, the reagent is less likely to linger and cause prolonged immune stimulation. As a result, experiments using such specialized reagents often report only mild cytokine changes or none at all. For instance, if one delivers an siRNA using Altogen’s kit, one would measure gene knockdown without the confounding factor of an overt inflammatory response that might otherwise modulate gene expression globally.

Of course, completely eliminating immune signaling is not always possible (or even desirable, if the goal is a vaccine or immunotherapy). But for most gene therapy applications in the liver, controlling inflammation is key to safety. Too strong an inflammatory reaction can damage liver cells or even cause systemic issues (like systemic inflammatory response syndrome). Researchers therefore include anti-inflammatory steroids or immune suppressants in some protocols when high doses of vectors are used. Fortunately, with careful design of the transgene (avoiding immunogenic sequences), use of high-purity vectors, and advanced delivery formulations, the liver can be transfected with surprisingly low immune noise.

Conclusion

Transfection-induced inflammatory signaling is an important consideration whenever genetic material is introduced into the liver. The liver’s innate immune system can be triggered by DNA or RNA through receptors like TLR9, RIG-I, and cGAS, leading to the release of cytokines such as IL-6, TNF-α, and type I interferons. These responses, if unmitigated, may not only confound experimental results but also pose safety risks in therapeutic settings. Through years of research, we have learned that the choice of transfection method and vector greatly influences the degree of inflammation. Techniques like hydrodynamic delivery surprisingly induce only weak immune activation on their own, whereas certain cationic polymers or lipids can provoke strong cytokine responses unless chemically modified to be more biocompatible. Modern liver transfection reagents, including those from Altogen Biosystems, illustrate the field’s progress: they achieve efficient gene delivery with minimal inflammatory signaling, as evidenced by their low cytotoxicity and targeted action. By minimizing off-target interactions and focusing delivery to hepatocytes, these reagents reduce the “danger signals” that cause immune cells to react.

In conclusion, understanding and managing the immune side of transfection enables more reliable and safer gene transfer into the liver. For investigators and clinicians, employing strategies to dampen innate immune sensing (through vector design or transient immune blockade) can significantly improve transfection outcomes. As gene therapies for liver diseases advance, maintaining a balance between effective delivery and immune quiescence will be paramount. Continued collaboration between immunologists and gene therapy researchers will yield even more refined methods to deliver genes to the liver “silently,” invoking the desired genetic changes without unwanted inflammatory noise.

Sources: Studies on cytokine induction by nonviral vectors; polymer modifications reducing IL-6/TNF release; hydrodynamic transfection immune profile; Altogen reagent characteristics.

.